2024-09-24T09:49:06-05:00 2023-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 3001 SUMMER STREET 5TH FLOOR EAST STAMFORD CT 06905 990 2023-01-01 061504413 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULT 2032290464 383 MAIN AVE 5TH FL NORWALK CT 06851 MICHAEL ANDREINI PRESIDENT & CEO 2032290464 2024-09-24 1 1 MELISSA MODELSON P01603524 2033232400 2024-09-23 2023 2024-08-08 14:25:15Z MICHAEL ANDREINI 383 MAIN AVE 5TH FL NORWALK CT 06851 137185152 0 X WWW.THEMMRF.ORG X 1998 CT SEE SCHEDULE O 17 16 78 300 0 0 42022114 30976388 2152800 1281492 670999 1692518 198561 192 45044474 33950590 4589741 8051387 0 0 10374937 11521963 0 0 5573068 23316052 22317479 38280730 41890829 6763744 -7940239 89097661 80227632 25407747 23942208 63689914 56285424 X SEE SCHEDULE O 0 0 4965510 650000 1281492 THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES.IN 2023, THE MMRF DEVELOPED THE HORIZON ADAPTIVE TRIALS PROGRAM. SLATED TO OPEN IN 2024, HORIZON WILL TEST TREATMENT STRATEGIES THROUGH TWO TRIALS IN PATIENTS WITH RELAPSED/REFRACTORY DISEASE AND THOSE WHO ARE NEWLY DIAGNOSED AND HAVE HIGH-RISK DISEASE. THE ADAPTIVE NATURE OF THE TRIALS ALLOWS INVESTIGATORS TO TEST MULTIPLE THERAPIES SIMULTANEOUSLY AND REDUCE THE AMOUNT OF TIME NEEDED TO EVALUATE NEW THERAPIES. INVESTIGATORS CAN THEN RAPIDLY EXPAND PATIENT COHORTS RECEIVING TREATMENT REGIMENS WITH POSITIVE OUTCOMES AND EFFICIENTLY CLOSE EXPERIMENTAL PROTOCOLS WITH LESS-THAN-OPTIMAL OUTCOMES. GROUNDBREAKING CLINICAL TRIALS LIKE HORIZON ARE ONLY POSSIBLE THROUGH LARGER-SCALE, MULTI-INSTITUTIONAL COOPERATION. THESE TRIALS ALLOW THE MMRC TO EXPLORE COMBINATION THERAPIES REGARDLESS OF MANUFACTURER, PUTTING THE MOST PROMISING SCIENCE AND THE URGENT NEED OF PATIENTS AHEAD OF PHARMACEUTICAL PROFITS OR INDUSTRY COMPETITION. 4698792 0 0 IN 2023, THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE FOR MYELOMA PATIENTS. THE ATLAS WILL DESCRIBE THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASE AND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH GUIDELINES AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM. 4364457 0 0 IN 2023, THE MMRF CONCLUDED ENROLLMENT IN THE MMRF CURECLOUD ("CURECLOUD") RESEARCH INITIATIVE, MAKING IT ONE OF THE LARGEST LONGITUDINAL DATA SETS IN MULTIPLE MYELOMA, WITH OVER 1,000 PATIENTS ENROLLED. THE DATA FROM THIS STUDY, WHICH INCLUDES CLINICAL GENOMIC, IMMUNE, AND PATIENT-REPORTED OUTCOMES, IS BEING ANALYZED IN ONGOING RESEARCH AND WILL BE MADE AVAILABLE TO RESEARCHERS TO HELP ANSWER IMPORTANT MYELOMA RESEARCH QUESTIONS AND INFORM FUTURE MMRF DATA-GENERATING INITIATIVES, ALL IN SUPPORT OF THE MMRF'S MISSION. 20938599 7401387 192 IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE FOR EACH AND EVERY PATIENT. 20938599 7401387 192 34967358 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 1 0 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 67 0 78 1 0 0 0 0 0 0 0 0 0 0 0 0 X 17 16 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA IL KS KY MD MA MI MN MS NH NJ NY NC OR PA RI SC TN VA WI WV X X X JOANNE PUGLIA 2036520207 383 MAIN AVE 5TH FLOOR NORWALK CT 06851 KATHY GIUSTI FOUNDER & DIRECTOR 20.00 X 183333 0 0 THOMAS CONHEENEY CHAIRMAN 2.00 X X 0 0 0 GERALD MCDOUGALL VICE CHAIRMAN 2.00 X X 0 0 0 KENNETH ANDERSON MD DIRECTOR 2.00 X 0 0 0 KAREN ANDREWS DIRECTOR 2.00 X 0 0 0 RODNEY GILMORE DIRECTOR 2.00 X 0 0 0 DAVID LUCCHINO DIRECTOR 2.00 X 0 0 0 LORI TAUBER-MARCUS DIRECTOR 2.00 X 0 0 0 HUGH MARTIN DIRECTOR 2.00 X 0 0 0 SUSAN MARVIN DIRECTOR 2.00 X 0 0 0 WILLIAM MCKIERNAN DIRECTOR 2.00 X 0 0 0 MICHAEL MORTIMER DIRECTOR 2.00 X 0 0 0 DAVID PARKINSON MD DIRECTOR 2.00 X 0 0 0 MARIE PINIZZOTTO MD DIRECTOR 2.00 X 0 0 0 ADRIAN ROSENKRANZ DIRECTOR 2.00 X 0 0 0 STEVE SHAK MD DIRECTOR 2.00 X 0 0 0 KIMBERLY WHITE DIRECTOR 2.00 X 0 0 0 MICHAEL ANDREINI PRESIDENT & CEO 40.00 X 527575 0 24958 ROBERT MIANI TREASURER & CFO 40.00 X 385910 0 28032 KAREN DIETZ SECRETARY, CAO & GENERAL COUNSEL 40.00 X 280128 0 35695 ANNE QUINN YOUNG CHIEF MISSION OFFICER 40.00 X 368426 0 23135 GEORGE MULLIGAN CHIEF SCIENTIFIC OFFICER 40.00 X 358470 0 39082 PETER KOSA MIF MANAGING DIR., THRU MAY 2023 40.00 X 247225 0 15580 CHRISTOPHER WILLIAMS VP OF ALLIANCE MANAGEMENT 40.00 X 237539 0 31093 EVA M LEPISTO VP OF INFORMATICS 40.00 X 225272 0 10378 HEARN CHO CHIEF MEDICAL OFFICER 32.00 X 223354 0 8934 KATIE WOZNIAK VP OF CLINICAL RESEARCH 40.00 X 210845 0 29597 MINDY FLINN VP OF DEVELOPMENT, THRU SEPT. 2023 40.00 X 166712 0 19369 GREG RUBENSTEIN VP OF MARKETING 40.00 X 218085 0 32026 CHARLES VOLPE DIRECTOR, PR & COMM., THRU DEC. 2023 40.00 X 204169 0 23980 TODD BROOKS SR PRINCIPAL GIFT OFFICER 40.00 X 200866 0 9243 JOANNE PUGLIA SR DIRECTOR FINANCE, CONTROLLER 40.00 X 195754 0 10193 MARK HAMILTON ASSOCIATE DIRECTOR, RESEARCH 40.00 X 187297 0 12462 4420960 0 353757 45 0 1 0 REDMEDED LLC 5 GREAT VALLEY PARKWAY SUITE 221 MALVERN PA 19355 CONTINUING MEDICAL EDUCATION 1578567 CYBER X DESIGNS LLC DBA ARTERIC 4270 IVY POINTE BLVD CINCINNATI OH 45245 MARKETING CONSULTANT 1524985 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE LEVY PLACE NEW YORK NY 10029 CONTRACT RESEARCH 1438990 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02215 CONTRACT RESEARCH 1151140 TGEN 445 N FIFTH STREET PHOENIX AZ 85004 CONTRACT RESEARCH 1122765 53 30976388 251490 30976388 RESEARCH & CLINICAL TRIALS 541610 1281492 1281492 1281492 1696550 1696550 192 192 103230530 103234562 -4032 -4032 -4032 33950590 1281684 0 1692518 X 7276387 7276387 775000 775000 3680642 2538092 375543 767007 6405349 4416994 653550 1334805 177382 122319 18099 36964 549023 378595 56018 114410 709567 489302 72398 147867 344764 318092 2182 24490 57505 53056 364 4085 60000 55358 380 4262 5662222 4435659 116454 1110109 2009835 1631552 12722 365561 1897212 1364508 3285 529419 1991345 1837287 12605 141453 207010 190995 1310 14705 669418 375653 9583 284182 670588 19692 650896 762057 717480 14749 29828 183372 169186 1161 13025 CLINICAL TRIAL/RESEARCH 7270131 7270131 TISSUE BANKING 532020 532020 41890829 34967358 1350403 5573068 X 303228 151177 0 152051 5060628 1373960 13092430 3484634 5229372 3195258 8274610 3739397 896043 715352 5002292 2364594 2964126 2637698 41091535 48157559 11719698 16363985 769219 559789 89097661 80227632 15173286 19417597 43261 980000 9131077 2808555 1060123 736056 25407747 23942208 X 56121149 53786450 7568765 2498974 63689914 56285424 89097661 80227632 X -7940239 1164786 -629037 X X 0 1 X 1 0 X 39651088 25012712 37089868 42022114 30976388 174752170 39651088 25012712 37089868 42022114 30976388 174752170 22428707 152323463 1349522 426629 100955 679638 1696550 4253294 6000 6000 179011464 14050153 0.85090 0.84330 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2022 AMOUNT: $ 6,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 635825 399566 236259 408670 253875 154795 3957797 1711153 2246644 2637698 CULLINAN MICA CORP. 3138051 F ABCURO, INC. 1411251 F INDAPTA THERAPEUTICS 2088027 F FORTIS THERAPEUTIC 500000 F CYTOIMMUNE THERAPEUTICS 1999995 F TRIUMVIRA IMMUNOLOGICS 1000001 F TELO THERAPEUTICS 1060000 F LUMINARY THERAPEUTICS 1000000 F KAHR MEDICAL LTD. 2666667 F NECTIN THERAPEUTICS 999995 F REVERB THERAPEUTICS 499998 F 16363985 OPERATING LEASE LIABILITY 736056 736056 X 34446110 1164786 794383 1959169 32486941 1463649 1463649 33950590 41221563 794383 794383 40427180 1463649 1463649 41890829 PART X, LINE 2: THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,463,649. PART XII, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,463,649. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 750000 NORTH AMERICA 0 0 GRANTMAKING 25000 MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS 3666662 NORTH AMERICA 0 0 INVESTMENTS 499998 0 0 0 0 0 0 4941660 0 4941660 EUROPE (INCLUDING ICELAND & GREENLAND) MAC GRANT 750000 WIRE 0 NORTH AMERICA SITE INVESTMENT GRANT 25000 WIRE 0 2 0 1 0 1 0 0 0 PART I, LINE 2: MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. SCHEDULE F, PART IV, LINE 1: THE ORGANIZATION IS REQUIRED TO FILE FORM 926 AS IT MEETS THE APPLICABLE FILING REQUIREMENT THRESHOLDS. SCHEDULE F, PART IV, LINE 3: THE ORGANIZATION IS NOT REQUIRED TO FILE FORM 5471 AS DOES NOT MEET THE APPLICABLE FILING REQUIREMENT THRESHOLDS OR OWNERSHIP AMOUNT. 1 BARBARA ANN KARMANOS CANCER HOSPITAL 4100 JOHN R STREET DETROIT MI 48201 201649466 501(C)(3) 100000 0 SITE INVESTMENT GRANT BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 612829 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY CITY OF HOPE 1500 EAST DUARTE ROAD MEDICAL OFFICE BLD 3RD FLOOR DURATE CA 91010 953435919 501(C)(3) 130000 0 SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY DANA FARBER CANCER INSTITUTE 44 BINEY ST BOSTON MA 02115 042263040 501(C)(3) 1050000 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION EMORY UNIVERSITY 1365 CLIFTON RD BLDG C ATLANTA GA 30322 580566256 501(C)(3) 613060 0 SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION HACKENSACK UNIVERSITY MEDICAL CENTER 360 ESSEX CENTER SUITE 302 HACKENSACK NJ 07601 221487576 501(C)(3) 101729 0 SITE INVESTMENT GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE PO BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 1964644 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY INDIANA UNIVERSITY 400 E 7TH STREET POPLARS 501 BLOOMINGTON IN 47405 356001673 501(C)(3) 7500 0 FELLOW LEVINE CANCER CENTER 1021 MOREHEAD MEDICAL DRIVE CHARLOTTE NC 28204 560529945 501(C)(3) 50000 0 SITE INVESTMENT GRANT MAYO CLINIC - ROCHESTER 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 405695 0 SITE INVESTMENT GRANT MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 100000 0 SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION OHIO STATE UNIVERSITY RESEARCH FOUNDATION B321 STARLING LOVING HALL 320 WEST 10TH AVENUE COLUMBUS OH 43210 316401599 501(C)(3) 55000 0 SITE INVESTMENT GRANT SARAH CANNON RESEARCH INSTITUTE LLC 3322 WEST END ROAD SUITE 900 NASHVILLE TN 37203 201557751 100000 0 SITE INVESTMENT GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVENUE MC 2115 CHICAGO IL 60637 362177139 STATE OF ILLINOIS 100000 0 SITE INVESTMENT GRANT, FELLOW UCSF MYELOMA RESEARCH PROGRAM 1855 FOLSOM STREET ROOM 423 SAN FRANCISCO CA 94103 946036493 501(C)(3) 150000 0 SITE INVESTMENT GRANT UNIVERSITY OF MICHIGAN 4310 CANCER CENTER 1500 EAST MEDICAL CENTER DRIVE ANN ARBOR MI 48109 386006309 STATE OF MICHIGAN 25000 0 SITE INVESTMENT GRANT UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BOULEVARD DALLAS TX 75390 756002868 STATE OF TEXAS 110000 0 SITE INVESTMENT GRANT WASHINGTON UNIVERSITY IN ST LOUIS 660 E EUCLID AVENUE ST LOUIS MO 63110 430653611 501(C)(3) 806802 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY BE THE MATCH FOUNDATION 500 N 5TH STREET MINNEAPOLIS MN 55401 411704734 501(C)(3) 10000 0 IMMUNOTHERAPY MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 42500 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 60000 0 IMMUNOTHERAPY 20 1 PART I, LINE 2: THE OVERALL RESEARCH BUDGET IS PRESENTED TO THE MMRF BOARD. THE BUDGET IS BROKEN DOWN INTO THREE MAIN CATEGORIES WHICH INCLUDE THE FOLLOWING GRANT TYPES: A) DATA BANK: MMRF-SPONSORED LONGITUDINAL MOLECULAR AND IMMUNE STUDIES (COMMPASS AND THE MMRF CURECLOUD). B) LEARNING NETWORK: GATEWAYS, DATA ANALYSIS INITIATIVES, TRANSLATIONAL SITE INVESTMENTS GRANTS (MMRF TRANSLATIONAL NETWORK), TRANSLATIONAL AND IMMUNE PROGRAM GRANTS, RESEARCH FELLOW GRANTS. C) CLINIC: CLINICAL- SITE INVESTMENT GRANTS, CLINICAL FUNDING AGREEMENT GRANTS, PRECISION MEDICINE GRANTS. THE BUDGET SPEND IS INITIALLY APPROVED BY THE PROGRAMMING COMMITTEE, AND THEN THE BOARD GIVES FINAL APPROVAL. 2. DURING THE YEAR, THERE ARE RESEARCH SPEND MEETINGS WITH THE CEO AND CFO TO DISCUSS PROGRESS ON MAKING THE AWARDS. ADDITIONALLY, ANY CHANGES OR REFORECASTS ARE REVIEWED. IF A CHANGE ARISES THAT IS GREATER THAN $1M, THEN IT IS PRESENTED TO THE AUDIT AND FINANCE COMMITTEE AS WELL AS THE PROGRAMMING COMMITTEE TO DISCUSS. 3. THERE ARE TWO DISTINCT TYPES OF GRANTS BEING AWARDED: CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. CLASSICAL RESEARCH GRANTS: GRANTS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE AREAS OF EXPERTISE. SCIENTIFIC RATINGS USE THE CURRENT NIH SCORING SYSTEM OF 1-9 WITH 1 DEMONSTRATING THE HIGHEST SCIENTIFIC MERIT AND 9 BEING THE LOWEST. EACH PROPOSAL IS EVALUATED BY TWO INDEPENDENT OUTSIDE REVIEWERS AND THE SCORES ARE AVERAGED TOGETHER. MOST GRANTS CHOSEN SCORE AT LEAST A 3 OR BETTER. ONCE THE GRANTS ARE RATED EXTERNALLY, FINAL REVIEW IS DONE BY THE MMRF RESEARCH LEADERSHIP AND RECOMMENDATIONS ARE MADE TO THE CEO AND CFO TO CONFIRM THE FINAL SELECTION. AFTER EACH GRANT TYPE AWARD IS MADE, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. AFTER THE FIRST PAYMENT THE RESEARCHER SENDS IN THE REQUIRED PROGRESS REPORT TO RECEIVE REMAINING PAYMENTS. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS THAT APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS: GRANT PROPOSALS TO SUPPORT MMRF/C CLINICAL OR TRANSLATIONAL SITES ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP IN COLLABORATION WITH OUTSIDE ADVISORS. THE MMRF RESEARCH LEADERSHIP THEN MAKES RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. AFTER EACH GRANT TYPE AWARD IS APPROVED, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. SUCH GRANTS ARE TYPICALLY RENEWED ANNUALLY OR ARE MULTI-YEAR IN NATURE. CONTINUATION/RENEWAL IS AWARDED BASED ON MILESTONES ESTABLISHED UPON INITIATION OF THE PROGRAM. A CONFLICT OF INTEREST POLICY IS IN PLACE AND A COMMITTEE REVIEWS ANY ISSUES THAT MIGHT ARISE WITH ANY GRANTS. X X X X 1 0 0 0 0 0 0 1 0 MICHAEL ANDREINI PRESIDENT & CEO 369875 0 150000 0 7700 0 15000 0 9958 0 552533 0 0 0 ROBERT MIANI TREASURER & CFO 255060 0 105000 0 25850 0 18108 0 9924 0 413942 0 0 0 GEORGE MULLIGAN CHIEF SCIENTIFIC OFFICER 271284 0 60000 0 27186 0 15000 0 24082 0 397552 0 0 0 ANNE QUINN YOUNG CHIEF MISSION OFFICER 257858 0 78000 0 32568 0 15000 0 8135 0 391561 0 0 0 KAREN DIETZ SECRETARY, CAO & GENERAL COUNSEL 205691 0 53000 0 21437 0 14789 0 20906 0 315823 0 0 0 CHRISTOPHER WILLIAMS VP OF ALLIANCE MANAGEMENT 193421 0 25000 0 19118 0 9800 0 21293 0 268632 0 0 0 PETER KOSA MIF MANAGING DIR., THRU MAY 2023 107135 0 122000 0 18090 0 5803 0 9777 0 262805 0 0 0 GREG RUBENSTEIN VP OF MARKETING 185712 0 22000 0 10373 0 9040 0 22986 0 250111 0 0 0 KATIE WOZNIAK VP OF CLINICAL RESEARCH 187259 0 8000 0 15586 0 6563 0 23034 0 240442 0 0 0 EVA M LEPISTO VP OF INFORMATICS 187905 0 25000 0 12367 0 8980 0 1398 0 235650 0 0 0 HEARN CHO CHIEF MEDICAL OFFICER 151078 0 43000 0 29276 0 8934 0 0 0 232288 0 0 0 CHARLES VOLPE DIRECTOR, PR & COMM., THRU DEC. 2023 155173 0 10000 0 38996 0 0 0 23980 0 228149 0 0 0 TODD BROOKS SR PRINCIPAL GIFT OFFICER 175000 0 16000 0 9866 0 8020 0 1223 0 210109 0 0 0 JOANNE PUGLIA SR DIRECTOR FINANCE, CONTROLLER 162654 0 18000 0 15100 0 7830 0 2363 0 205947 0 0 0 MARK HAMILTON ASSOCIATE DIRECTOR, RESEARCH 160657 0 13000 0 13640 0 7450 0 5012 0 199759 0 0 0 MINDY FLINN VP OF DEVELOPMENT, THRU SEPT. 2023 132654 0 25000 0 9058 0 6313 0 13056 0 186081 0 0 0 KATHY GIUSTI FOUNDER & DIRECTOR 0 0 0 0 183333 0 0 0 0 0 183333 0 0 0 PART I, LINE 4A CHARLES VOLPE, DIRECTOR, PR & COMMUNICATIONS, RECEIVED A SEVERANCE PAYMENT OF $31,500 INCLUDED IN HIS 2023 FORM W-2. PART I, LINE 7 INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2023, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2023 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES. X 21 251490 AVG. SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. FORM 990, PART I, LINE 1: MMRF ACCOMPLISHMENTS FOR 2023: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AND ITS WHOLLY OWNED SUBSIDIARIES, THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC ("MMRC") AND MYELOMA INVESTMENT FUND, LLC ("MIF"), COLLECTIVELY REFERRED TO AS "THE MMRF," IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. THE MMRF DRIVES THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGES DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES AND EMPOWERS MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO THE MMRF'S MISSION IS ITS COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES THEY PURSUE. SINCE ITS INCORPORATION ON JANUARY 13, 1998, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, OPENED NEARLY 100 CLINICAL TRIALS, AND HELPED BRING 15+ FDA APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. IN 2023, THE MMRF INVESTED NEARLY $36 MILLION THIS PAST YEAR IN URGENT RESEARCH PROJECTS AND SUPPORT SERVICES FOR PATIENTS. WE DIRECTLY INVESTED IN TWO NEW PROMISING THERAPIES THROUGH THE MYELOMA INVESTMENT FUND (MIF), FUELED THREE MYELOMA ACCELERATOR CHALLENGE (MAC) PROGRAM PROJECTS FOR $21 MILLION WITH THE POWER TO DELIVER NEW SCIENTIFIC ADVANCES, AND SERVED 16,500 PATIENTS WITH EDUCATIONAL AND SUPPORT SERVICES TO IMPROVE THEIR OUTCOMES. WE ALSO WELCOMED THE INAUGURAL COHORT OF THE MMRF SCHOLARS PROGRAM, WHICH RECRUITS EARLY-CAREER BLACK RESEARCHERS TO THE FIELD OF MYELOMA. FORM 990, PART III, LINE 1: THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. WE DRIVE THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGE DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES AND EMPOWER MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO OUR MISSION IS OUR COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES WE PURSUE. SINCE OUR INCEPTION, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, OPENED NEARLY 100 CLINICAL TRIALS, AND HELPED BRING 15+ FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. FORM 990, PART VI, SECTION A, LINE 2 KATHY GIUSTI, FOUNDER & FORMER CHIEF MISSION OFFICER, AND KAREN ANDREWS, BOARD MEMBER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO ANY DIRECTOR, OFFICER, OR MEMBER OF A STANDING OR ADVISORY COMMITTEE WITH POWERS DELEGATED BY THE MMRF BOARD OF DIRECTORS WHO MAY HAVE A DIRECT OR INDIRECT FINANCIAL INTEREST (I.E. "INTERESTED PERSON"). DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR AUDIT COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE AUDIT COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR AUDIT COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR AUDIT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR AUDIT COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE AUDIT COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE AUDIT COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR AUDIT COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR AUDIT COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE HR COMMITTEE OF THE BOARD OF DIRECTORS. COMPENSATION IS BENCHMARKED AGAINST OTHER 501(C)(3)'S, RESEARCH ORGANIZATIONS, THIRD PARTY COMPENSATION DATABASE AND THEN REVIEWED BY THE COMPENSATION COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2023. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 1,620,848. MANAGEMENT AND GENERAL EXPENSES 86,606. FUNDRAISING EXPENSES 832,721. TOTAL EXPENSES 2,540,175. MEDICAL PROFESSIONALS: PROGRAM SERVICE EXPENSES 2,462,466. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 206,479. TOTAL EXPENSES 2,668,945. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 352,345. MANAGEMENT AND GENERAL EXPENSES 29,848. FUNDRAISING EXPENSES 70,909. TOTAL EXPENSES 453,102. FORM 990, PART XI, LINE 9: LOSS ON DISPOSAL OF ASSETS -629,037. FORM 990, PART XII, LINE 2C: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR. MYELOMA INVESTMENT FUND LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471162865 VENTURE PHILANTHROPY FUND DE 1588166 21345357 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471142650 FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH CT 4771613 1176615 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC